Ignite Creation Date:
2024-05-06 @ 12:16 PM
Last Modification Date:
2024-10-26 @ 12:56 PM
Study NCT ID:
NCT03719898
Status:
WITHDRAWN
Last Update Posted:
2021-01-05
First Post:
2018-10-16
Brief Title:
Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
Sponsor:
Fox Chase Cancer Center
Organization:
Fox Chase Cancer Center
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Anaplastic Large Cell Lymphoma ALK-Positive |
Keywords: